Advertising Zone 10

Lytix Biopharma is joining a new investigator-initiated Phase II study, ALETTA, that will test its lead candidate ruxotemitide in combination with ipilimumab and nivolumab in patients with early-stage, resectable melanoma – a second major checkpoint-inhibitor combination alongside the company’s existing pembrolizumab work.

Norwegian biotech Circio Holding has entered a research collaboration with US-based Full Circles Therapeutics to combine their respective circular nucleic acid platforms, aiming to build non-viral, re-dosable in vivo cell therapies as an alternative to conventional approaches like CAR-T.

The Danish biotech has triggered a milestone payment from AbbVie after the pharma giant advanced ABBV-295, a long-acting amylin analog for chronic weight management, into a Phase 2 clinical trial – the latest payout under the pair’s 2025 obesity licensing deal.

Finnish medtech company Nexstim has received an order for its latest-generation NBS 6 navigated brain stimulation system from an existing hospital customer in Europe, as the customer upgrades from an earlier-generation platform.